6 March 2014 - Patients with advanced cervical cancer in England have been given the chance of accessing treatment with Roche's Avastin (bevacizumab) on the National Health Service, after it became the latest medicine to be added to the country's Cancer Drugs Fund.

The decision, by NHS England’s Chemotherapy Clinical Reference Group, was made on the back of clinical trials showing that the drug can extend the lives of women with advanced cervical cancer by nearly four months compared to chemotherapy alone.

For more details, go to: http://www.pharmatimes.com/Article/14-03-06/Avastin_on_CDF_list_for_advanced_cervical_cancer.aspx#ixzz2vDyko0g5